These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 9733353

  • 1. Pharmacokinetics and pharmacodynamics of sibrafiban (Ro 48-3657), an orally active IIb/IIIa antagonist, administered alone or in combination with heparin, aspirin, and recombinant tissue-type plasminogen activator in beagles.
    Modi NB, Lin YS, Reynolds T, Shaheen A, Christian BJ.
    J Cardiovasc Pharmacol; 1998 Sep; 32(3):397-405. PubMed ID: 9733353
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetics and pharmacodynamics of sibrafiban, an orally administered GP IIb/IIIa antagonist, following coadministration of aspirin and heparin.
    Reimann JD, Modi NB, Novotny W.
    J Clin Pharmacol; 2000 May; 40(5):488-95. PubMed ID: 10806602
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics and pharmacodynamics of Ro 44-3888 after single ascending oral doses of sibrafiban, an oral platelet aggregation inhibitor, in healthy male volunteers.
    Wittke B, Mackie IJ, Machin SJ, Timm U, Zell M, Goggin T.
    Br J Clin Pharmacol; 1999 May; 47(5):521-30. PubMed ID: 10336576
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetics and pharmacodynamics of sibrafiban, an orally administered IIb/IIIa antagonist, in patients with acute coronary syndrome.
    Modi NB, Novotny W, Reimann JD, Cannon CP, Braunwauld E.
    J Clin Pharmacol; 1999 Jul; 39(7):675-84. PubMed ID: 10392322
    [Abstract] [Full Text] [Related]

  • 5. Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Thrombolysis in Myocardial Infarction.
    Cannon CP, McCabe CH, Borzak S, Henry TD, Tischler MD, Mueller HS, Feldman R, Palmeri ST, Ault K, Hamilton SA, Rothman JM, Novotny WF, Braunwald E.
    Circulation; 1998 Feb 03; 97(4):340-9. PubMed ID: 9468207
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics and pharmacodynamics of TP-9201, a gpIIbIIIa antagonist, administered in combination with recombinant tissue-type plasminogen activator, heparin, and aspirin in beagles.
    Modi NB, Reynolds T, Baughman SA, Thomas DA, Paasch BD, Smith SY.
    J Cardiovasc Pharmacol; 1996 Jan 03; 27(1):105-12. PubMed ID: 8656642
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetics and pharmacodynamics of sibrafiban alone or in combination with ticlopidine and aspirin.
    Wittke B, Ensor H, Chung J, Birnböck H, Lausecker B, Ertel SI, MacKie IJ, Machin SJ.
    Br J Clin Pharmacol; 2000 Mar 03; 49(3):231-9. PubMed ID: 10718778
    [Abstract] [Full Text] [Related]

  • 8. Prohemorrhagic and bleeding time activities of recombinant tissue plasminogen activator, heparin, aspirin, and a glycoprotein IIb/IIIa antagonist.
    Mihara K, Aoki T, Moriguchi A, Maeda M, Furuichi Y, Matsuoka N, Mutoh S.
    J Neurotrauma; 2005 Nov 03; 22(11):1362-73. PubMed ID: 16305324
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetics, pharmacodynamics and tolerability of a potent, non-peptidic, GP IIb/IIIa receptor antagonist following multiple oral administrations of a prodrug form.
    Refino CJ, Modi NB, Bullens S, Pater C, Lipari MT, Robarge K, Blackburn B, Beresini M, Weller T, Steiner B, Bunting S.
    Thromb Haemost; 1998 Jan 03; 79(1):169-76. PubMed ID: 9459344
    [Abstract] [Full Text] [Related]

  • 10. Sibrafiban. RO 483657, RO 483657-000, Xubix.
    Drugs R D; 1999 May 03; 1(5):387-9. PubMed ID: 10566072
    [No Abstract] [Full Text] [Related]

  • 11. Long-term oral platelet glycoprotein IIb/IIIa receptor antagonism with sibrafiban after acute coronary syndromes: study design of the sibrafiban versus aspirin to yield maximum protection from ischemic heart events post-acute coronary syndromes (SYMPHONY) trial. Symphony Steering Committee.
    Newby LK.
    Am Heart J; 1999 Aug 03; 138(2 Pt 1):210-8. PubMed ID: 10426831
    [Abstract] [Full Text] [Related]

  • 12. Orally active fibrinogen receptor antagonists. 2. Amidoximes as prodrugs of amidines.
    Weller T, Alig L, Beresini M, Blackburn B, Bunting S, Hadváry P, Müller MH, Knopp D, Levet-Trafit B, Lipari MT, Modi NB, Müller M, Refino CJ, Schmitt M, Schönholzer P, Weiss S, Steiner B.
    J Med Chem; 1996 Aug 02; 39(16):3139-47. PubMed ID: 8759635
    [Abstract] [Full Text] [Related]

  • 13. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. The SYMPHONY Investigators. Sibrafiban versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-acute Coronary Syndromes.
    Lancet; 2000 Jan 29; 355(9201):337-45. PubMed ID: 10665552
    [Abstract] [Full Text] [Related]

  • 14. Effects of heparin, aspirin and a synthetic platelet glycoprotein IIb-IIIa receptor antagonist (Ro 43-5054) on coronary artery reperfusion and reocclusion after thrombolysis with tissue-type plasminogen activator in the dog.
    Roux SP, Tschopp TB, Kuhn H, Steiner B, Hadváry P.
    J Pharmacol Exp Ther; 1993 Jan 29; 264(1):501-8. PubMed ID: 8423548
    [Abstract] [Full Text] [Related]

  • 15. Effect of aspirin on platelet desaggregation induced by SR121566, a potent GP-IIb/IIIa antagonist.
    Savi P, Bernat A, Lalé A, Roque C, Zamboni G, Herbert JM.
    Platelets; 2000 Feb 29; 11(1):43-8. PubMed ID: 10938881
    [Abstract] [Full Text] [Related]

  • 16. Safety, tolerability, pharmacokinetics, and time course of pharmacologic response of the active metabolite of roxifiban, XV459, a glycoprotein IIb/IIIa antagonist, following oral administration in healthy volunteers.
    Pieniaszek HJ, Sy SK, Ebling W, Fossler MJ, Cain VA, Mondick JT, Ma S, Kornhauser DM.
    J Clin Pharmacol; 2002 Jul 29; 42(7):738-53. PubMed ID: 12092741
    [Abstract] [Full Text] [Related]

  • 17. Sibrafiban.
    Dooley M, Goa KL.
    Drugs; 1999 Feb 29; 57(2):225-30; discussion 231-2. PubMed ID: 10188763
    [Abstract] [Full Text] [Related]

  • 18. Bleeding time prolongation and bleeding during infusion of recombinant tissue-type plasminogen activator in dogs: potentiation by aspirin and reversal with aprotinin.
    Garabedian HD, Gold HK, Leinbach RC, Svizzero TA, Finkelstein DM, Guerrero JL, Collen D.
    J Am Coll Cardiol; 1991 Apr 29; 17(5):1213-22. PubMed ID: 1706738
    [Abstract] [Full Text] [Related]

  • 19. Inhibitory effect of a novel orally active GP IIb/IIIa inhibitor, SC-54684A on intimal thickening in the guinea pig femoral artery.
    Umemura K, Nishiyama H, Kikuchi S, Kondo K, Nakashima M.
    Thromb Haemost; 1996 Nov 29; 76(5):799-806. PubMed ID: 8950793
    [Abstract] [Full Text] [Related]

  • 20. Effects of glycoprotein IIb/IIIa antagonists on platelet activation: development of a transfer method to mimic peak to trough receptor occupancy.
    Billheimer JT, He B, Spitz SM, Stern AM, Seiffert D.
    Thromb Res; 2002 Sep 15; 107(6):303-17. PubMed ID: 12565717
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.